Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)

Overview of attention for article published in BMJ Open, February 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter: 10 X users
patent: 5 patents

wikipedia: 1 Wikipedia page

Readers on

mendeley: 86 Mendeley

So far, Altmetric has seen 10 X posts from 10 X users, with an upper bound of 16,514 followers.

@AlexMcLellan100 We need the efficacy of a CD28 CAR T cell without the neurotoxicity. Our phase 1 ENABLE trial should report within months… https://t.co/DZ2ceMXXK0

RT @CARTTherapy: Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 6 additional X posts.